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EDITORIAL COMMENT
The Points for Pacing*
Lynne Warner Stevenson, MD, FACC
Boston, Massachusetts
In this issue of the Journal, the study by Higgins et al. (1)
from the trial of resynchronization therapy provides the
opportunity to assess the current status of both the appli-
cation of biventricular pacing and the construction of trial
end points for new therapies in heart failure (HF). The
devices used in this trial clearly improved functional capacity
in those patients with major functional limitation at base-
line, a finding that reinforces the functional benefit seen
with similar devices and populations in other trials. The
strength and relevance of this emerging evidence stand
despite the interposition of an end point that did not show
benefit in this trial.
See page 1454
FUNCTIONAL BENEFIT FOR ADVANCED HF
Therapies proven beneficial for HF have done so largely by
showing decreases in disease progression and mortality
(2–5). The third target of therapy is the limiting symptoms
of HF. It is this third target that has been hit squarely by
biventricular pacing in appropriate candidates.
Of 581 patients originally identified in the trial, 490
patients were randomized as planned 30 days after the
procedure. Of the 91 patients not randomized, 14 withdrew
before the procedure and 1 withdrew after the procedure, 66
did not have successful coronary sinus lead insertion, and 10
died (2 of defibrillator testing complications, 5 of HF, 2 of
other cardiac causes, and 1 of unspecified reasons). It is a
strength of this trial that optimization of medical therapy
took place after the procedure for 30 days, during which
40% of New York Heart Association (NYHA) functional
class III to IV patients improved to class I to II whereas 19%
of class II patients worsened, changes that might otherwise
have clouded the effect of the intervention. Nonetheless, the
trial population for analysis might be considered to be the
original 581 patients, as was done for the meta-analysis of
biventricular pacing trials (6), rather than the 480 patients
(84%) randomized at 30 days after device implantation. The
current trial is an amalgam of both transthoracic (11%) and
transvenous devices (89%) and three-month and six-month
follow-up. The original end point was peak oxygen con-
sumption, a rigorous measurement of functional capacity.
Multiple factors apparently influenced the decision to
change the end point to a composite of mortality, HF
hospitalizations, and ventricular tachyarrhythmias requiring
therapy.
Functional capacity improved significantly in the overall
patient cohort, as indicated by an average increase of 1
ml/kg/min versus no change in peak oxygen consumption
and an increased 6-min walk distance of 35 versus 17 m.
These changes were driven by changes in the patients with
NYHA functional class III to IV because only minor
improvements could occur in the patients who had few
symptoms at baseline. Improvements in the quality of life
questionnaire and NYHA functional class were also seen in
the patients with class III to IV symptoms at baseline. These
more subjective changes lend support to the overall picture
of clinical improvement, but it is harder to interpret if
patients and physicians recognized the active therapy.
There is now a robust body of evidence supporting the
functional benefit in patients with major symptoms of HF.
The data from this experience are comparable to those from
the Pacing Therapies for Congestive Heart Failure
(PATH-CHF), MUSTIC, MIRACLE, and MIRACLE-
ICD trials (7–10). The limitation of symptomatic benefit to
those with NYHA functional class III or worse symptoms
also is consistent with previous experience (Fig. 1). In the
MIRACLE-ICD trial of a similar population requiring
ICD therapy, patients who were NYHA functional class II
had good functional capacity at baseline with little evidence
for any increase (9).
The post-approval experience with biventricular pacing
has provided reassurance that the enthusiasm of investiga-
tors and patients perceiving dramatic clinical improvement
during the original trials has been warranted. At the extreme
end, patients undergoing biventricular pacing are frequently
leaving the waiting list for cardiac transplantation (11). The
magnitude of early benefit for functional capacity in the
trials and in office settings far exceeds that described for the
initiation of angiotensin-converting enzyme inhibitors or
beta-adrenergic receptor antagonists (3,12). While decreas-
ing disease progression and prolonging survival, the phar-
macologic therapies may prevent worsening of functional
capacity more effectively than they have improved it once it
has declined, with the exception of diuretics for symptom-
atic fluid overload. In fact, the inability of quality of life
measures to reliably identify clinical improvement on med-
ications led to some question of whether the tools were
sufficiently sensitive. The recent trials of biventricular pac-
ing have validated the functional benefit of this therapy but
have also validated our ability to identify major symptomatic
improvement when it occurs in this HF population.
SURVIVAL AND DISEASE PROGRESSION
Measurable improvement in functional capacity and quality
of life represents an intrinsically worthwhile target for
therapy in patients with limiting symptoms of HF. Al-
though disease progression and survival do not need to be
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improved for this therapy to be viable, any worsening of
these end points would be of concern. Current data indicate
no worsening of the more solid end points of hospitaliza-
tions and mortality. It has been suggested that biventricular
pacing may increase the risk of torsade de pointes (13), but
the current trial and others have found no evidence of
increased clinical tachyarrhythmias.
There is in fact a strong trend shown here for decreased
hospitalizations, as one would expect from a therapy that
improves symptoms without major adverse effects. Because
the severity of HF and prognosis are mirrored in the
frequency of hospitalization, we might then expect that
robust symptomatic improvement could be associated with
better survival. The meta-analysis of biventricular pacing
trials (14) showed a 51% decrease in HF mortality as
described by Bradley et al. (6). Preliminary data from the
recently concluded COMPANION trial indicates a de-
crease in total mortality as well. It should be emphasized,
however, that such an improvement in survival might not be
required of a therapy that can stimulate sustained improve-
ment in functional capacity when stacked onto the multiple
therapies already recommended for survival.
Resynchronization is associated acutely with improved
contractility measured as dP/dt, decreased mitral regurgita-
tion, and lower left ventricular filling pressures (14,15).
Maintenance of these improvements might be expected to
lead to chronic remodeling, which was seen for NYHA
functional class II as well as class III/IV HF in this
experience and has been observed previously to a modest
degree with both left ventricular size and ejection fraction
(16). The consistent improvement in systolic blood pressure
additionally allows up-titration of the medications with
potential remodeling benefits. Caution is appropriate, how-
ever, when interpreting parameters of remodeling in this
setting. The pacing itself may cause immediate functional
changes that will partially revert as soon as pacing is halted.
Perhaps more important, surrogate end points that do not
carry intrinsic value for survival or function can be altered in
ways that bypass the desired effect, particularly with a novel
type of therapy. The surgical left ventriculectomy procedure
as put forth by Batista decreased both left ventricular size
and ejection fraction but most patients went on to cardiac
replacement therapies or died (17). It is reassuring that
biventricular pacing does not worsen parameters of disease
progression. However, disease progression does not have to
be improved to justify biventricular pacing to improve
symptoms that limit daily life. If consideration of biven-
tricular pacing extends to patients without limiting symp-
toms, such as in the NYHA functional class II patients with
ICD indications in this trial, the benefit to decrease disease
progression would have to be robust and confirmed with
clinical end points over a longer trial period.
WHO BENEFITS FROM RESYNCHRONIZATION?
Ambulatory patients with severe symptoms on standard oral
medications seem most likely to derive benefit. Within that
population, the trials have focused on patients with QRS
width over 130 ms, although most trial subjects have had
QRS duration over 160 ms. The QRS duration does not
reliably predict the degree of dyssynchrony seen on echo-
cardiogram or the magnitude of clinical improvement (18).
Our current knowledge remains very limited in terms of the
most appropriate subjects, the optimal lead positions, and
the adjustment of atrioventricular, interventricular, and
intraventricular synchrony.
Biventricular pacing as currently provided does not im-
pact on the majority of patients with advanced HF. When
calculating the potential target population, it should be
borne in mind that only one-half of HF occurs with reduced
left ventricular ejection fraction. Among patients with
persistent functional limitation and low left ventricular
ejection fraction, the proportion with a favorable pattern of
dyssynchrony as currently determined by QRS duration and
morphology is in the range of 30%. Positioning in the
coronary sinus is possible in 85% to 95% of cases. Occa-
sional deaths result from coronary sinus injury or from
testing of the defibrillator function of combined devices.
After successful implantation, perhaps 5% to 15% of pa-
tients have problems with diaphragmatic pacing or lead
instability that prevent continued pacing. Of those receiving
pacing, improvement is seen in approximately 60% to 70%.
At present, biventricular pacing is thus predicted to improve
clinical status for 15% to 20% of patients with advanced HF
and reduced left ventricular ejection fraction. Extension to
patients with atrial fibrillation (19) or to chronic right
ventricular pacemaker dependence is under investigation.
FROM THE BEGINNING TO END POINTS
The major end points of therapy for HF are survival,
functional capacity, and disease progression. Embarking
upon a trial involves selection of an end point that is
measurable and interpretable, sensitive to the therapy being
tested, and clinically relevant, as summarized by Fleming
Figure 1. Estimated impact of successful biventricular (Bi-V) pacing in
patients typical of those in the major trials. Good quality of life is calculated
as 105 minus the Minnesota Living with Heart Failure Questionnaire score
(therefore, a higher score is better on this graph), shown in open bars.
Solid bars are peak oxygen consumption (VO2) during exercise testing.
For comparison, average values at baseline are superimposed from the
population with mild-to-moderate heart failure in the Vasodilator Heart
Failure Trials (V-HeFT) (3).
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and DeMets (20). Choosing the “right” end point for a trial
often involves compromise between the best information
needed to justify use of a therapy and the best chance of
having a “positive” trial.
The construction of end points for HF can be seen as an
emerging craft. It has evolved from a single component in
early trials to the complex composite. The dual composite is
appropriate for key end points other than mortality, such as
hospitalization, to allow for competing outcomes. The
patient who is dead cannot be hospitalized but must be
counted as a bad outcome. Other composites have become,
however, increasingly complex. In the current trial, death
and hospitalization were combined with ventricular tachy-
arrhythmias. This component may have been added to
balance efficacy with risk; torsade de pointes has been
suggested to be triggered by the inhomogeneity of biven-
tricular pacing (13). Alternatively, at the time the study was
designed, there was some optimism that ventricular arrhyth-
mias would be decreased by biventricular pacing. Compos-
ites can become even more complex to combine feel-good
scales with mortality and other adverse events. In some
trials, composites may be designed for statistical success that
then allows consideration of more vital secondary end
points.
In this trial, the end point chosen was highly relevant but
not sensitive to the treatment effect. Is the evidence for
functional benefit weakened in this trial because the primary
end point was not met? The power to exclude chance is not
the same as truth. There is generally a truth that ultimately
emerges, even if sometimes delayed or ignored. Biventricu-
lar pacing does improve functional capacity for many pa-
tients, whether functional capacity is the primary end point,
the 19th, or absent from the list. The choice and success of
the end point have profound importance for the initial
sponsors. The truth, however, remains impervious to the
prediction or parsimony of its seekers.
The trial of biventricular pacing reported by Higgins et al.
(1) re-enforces the rapid acceptance of this new technology
as treatment for the symptoms in advanced heart failure.
Support is building for the hypothesis that resynchroniza-
tion may also influence disease progression, as measured by
the surrogates established for pharmacologic therapy. To
extend this procedure to prevent HF progression earlier in
the course of disease would require further trials, with
careful consideration of new end points specific to pacing
therapies.
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